165 related articles for article (PubMed ID: 10665560)
1. Sirolimus-tacrolimus combination immunosuppression.
McAlister VC; Gao Z; Peltekian K; Domingues J; Mahalati K; MacDonald AS
Lancet; 2000 Jan; 355(9201):376-7. PubMed ID: 10665560
[TBL] [Abstract][Full Text] [Related]
2. Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation.
Sageshima J; Ciancio G; Chen L; Dohi T; El-Hinnawi A; Paloyo S; Misawa R; Ekwenna O; Yatawatta A; Burke GW
Clin Transplant; 2014 Jul; 28(7):797-801. PubMed ID: 24779669
[TBL] [Abstract][Full Text] [Related]
3. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.
McAlister VC; Peltekian KM; Malatjalian DA; Colohan S; MacDonald S; Bitter-Suermann H; MacDonald AS
Liver Transpl; 2001 Aug; 7(8):701-8. PubMed ID: 11510015
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
5. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients.
Bechstein WO; Paczek L; Wramner L; Squifflet JP; Zygmunt AJ;
Transplant Proc; 2013; 45(6):2133-40. PubMed ID: 23953523
[TBL] [Abstract][Full Text] [Related]
6. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation.
MacDonald AS
Transplant Proc; 2003 May; 35(3 Suppl):201S-208S. PubMed ID: 12742497
[TBL] [Abstract][Full Text] [Related]
8. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
Ravichandran P; Natrajan T; Jaganathan R
Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
[TBL] [Abstract][Full Text] [Related]
10. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
11. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
Hanto DW; Chudzinski R
Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
[No Abstract] [Full Text] [Related]
12. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children.
Pollock-Barziv SM; Finkelstein Y; Manlhiot C; Dipchand AI; Hebert D; Ng VL; Solomon M; McCrindle BW; Grant D
Pediatr Transplant; 2010 Dec; 14(8):968-75. PubMed ID: 21040278
[TBL] [Abstract][Full Text] [Related]
13. Post-liver transplantation immunosuppression: the song does not remain the same.
Yoshida EM
Can J Gastroenterol; 2002 Jan; 16(1):65-6. PubMed ID: 11826341
[No Abstract] [Full Text] [Related]
14. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
[TBL] [Abstract][Full Text] [Related]
15. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
16. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants.
Sindhi R; Ganjoo J; McGhee W; Mazariegos G; Reyes J
Transplant Proc; 2002 Aug; 34(5):1972-3. PubMed ID: 12176651
[No Abstract] [Full Text] [Related]
17. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
[TBL] [Abstract][Full Text] [Related]
18. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
Knight RJ; Kerman RH; McKissick E; Lawless A; Podder H; Katz S; Van Buren CT; Kahan BD
Clin Transplant; 2008; 22(5):645-50. PubMed ID: 18657156
[TBL] [Abstract][Full Text] [Related]
19. Advances in immunosuppression for pancreas transplantation.
Singh RP; Stratta RJ
Curr Opin Organ Transplant; 2008 Feb; 13(1):79-84. PubMed ID: 18660711
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
